is tirzepatide being taken off the market Did FDA Ban Compounded Semaglutide and Tirzepatide? why is tirzepatide being taken

Active ingredient : Semaglutide Used in week 58 of dose escalation (after 0.25 mg) Supports weight loss , appetite suppression, and reduced food cravings Subcutaneous injection in pre-filled FlexTouch pen (4 doses per pen) Mimics GLP-1 hormone to signal fullness and regulate appetite Backed by clinical data for sustained weight reduction and cardiovascular benefit Adolescent and adult use in patients meeting BMI and weight criteria WEGOVY FLEXTOUCH 0.5mg (ITALIAN) Indications The 0.5 mg strength is not a therapeutic dose but an intermediate step to help patients reach the effective maintenance dose (2.4 mg)

This means that estrogen and progesterone levels will be better balanced

doi:10.1104/pp.118.4.1327

10.1007/s11695-021-05251-x 54

Phase one is 9%, phase two is 12%, phase three is 29% with the rest of it coming from that early basic research, drug discovery, preclinical studies, and a little bit later with the regulatory review